Ascendis Pharma AS (ASND)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $18.06B
Last updated: Nov 17, 2026 at 11:05 AM ET
Ascendis Pharma AS (ASND) Valuation Multiples
Ascendis Pharma AS (ASND) trades at 13.5x sales and 10.8x book value. Its P/S of 13.5x is below its 5-year median of 23.9x.
Current Multiples
ASND reports in EUR, so earnings multiples appear here only when its per-share earnings can be confirmed. Its free cash flow yield is 3.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 13.5x |
| Price to book | 10.8x |
| EV/EBITDA | 60.8x |
| Price to FCF | 31.6x |
| EV/FCF | 30.6x |
| PEG | N/A |
| FCF yield | 3.2% |
Historical Medians
Against its 10-year medians, its P/S is 90.5% below 141.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 13.5x | 23.9x | 141.6x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 15.8x in 2025 to 811.8x in 2021. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $213.24 | 15.8x | N/A |
| 2024 | $137.67 | 20.9x | N/A |
| 2023 | $125.95 | 24.4x | N/A |
| 2022 | $122.13 | 127.9x | 24.3x |
| 2021 | $134.53 | 811.8x | 7.2x |
| 2020 | $166.78 | N/A | 8.8x |
| 2019 | $139.12 | 425.0x | 10.0x |
| 2018 | $62.65 | 223.8x | 8.5x |
| 2017 | $40.06 | 766.8x | 6.9x |
| 2016 | $20.24 | 104.9x | 3.5x |
P/E history is shown only for companies that report in US dollars.
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ASND
Is ASND stock overvalued?
GNG's valuation label for ASND is Undervalued.
What is ASND's price to sales ratio?
Ascendis Pharma AS has a price to sales ratio of 13.5x.
ASND pages: Overview, Financials, Valuation, Competitors